Lucid Capital initiated coverage of Genelux (GNLX) with a Buy rating and $10 price target Genelux is a late clinical-stage biotechnology company focused on utilizing oncolytic viral immunotherapies for the treatment of cancer, the analyst tells investors in a research note. The firm sees a “low hanging fruit” opportunity for lead candidate Olvi-Vec in platinumresistant/refractory ovarian cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNLX: